For example, breast cancer patients positive for gains in the human epidermal growth factor receptor 2 (HER2) gene are eligible for treatment with trastuzumab [4], while gains in 14q32.33 are predictive of resistance and progression-free response to platinum therapy in epithelial ovarian cancer [5]. Here, ERBB2 is linked to breast carcinoma.